Patent: 9,862,772
✉ Email this page to a colleague
Summary for Patent: 9,862,772
Title: | Compositions and methods |
Abstract: | The invention relates to a composition comprising an anchor region capable of binding to a plasma cell; and a binding region associated with the anchor region, wherein the binding region binds a specific plasma cell antibody. |
Inventor(s): | Radbruch; Andreas (Berlin, DE), Hiepe; Falk (Berlin, DE), Taddeo; Adriano (Berlin, DE), Gerl; Velia (Berlin, DE), Hoyer; Bimba F. (Berlin, DE), Chang; Hyun-Dong (Berlin, DE), Theiel; Andreas (Berlin, DE) |
Assignee: | BEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (DRFZ) (Berlin, DE) |
Application Number: | 14/426,650 |
Patent Claims: | see list of patent claims |
Details for Patent 9,862,772
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-09-07 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2032-09-07 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2032-09-07 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2032-09-07 |
Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 03/28/2017 | ⤷ Try a Trial | 2032-09-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |